Diamyd Medical

Diamyd Medical is a Swedish biopharmaceutical company that specializes in the development of pharmaceutical treatments for diabetes and other serious inflammatory diseases. The company's primary focus is on the development of the diabetes vaccine Diamyd®, which is currently in clinical trials.

History[edit | edit source]

Diamyd Medical was founded in 1996 with the aim of finding a cure for Type 1 diabetes. The company's name, Diamyd, is derived from the words "diabetes" and "amyloid", which refers to the protein deposits that are found in the pancreas of individuals with Type 1 diabetes.

Diamyd®[edit | edit source]

Diamyd® is a GAD65-based diabetes vaccine that is currently in clinical trials. The vaccine is designed to halt the autoimmune attack on the insulin-producing beta cells in the pancreas, thereby preserving the body's ability to produce insulin.

The vaccine is based on the protein GAD65, which is a major target of the autoimmune response in Type 1 diabetes. By administering the vaccine, the aim is to reprogram the immune system to tolerate the body's own GAD65, thereby halting the autoimmune attack.

Clinical Trials[edit | edit source]

The clinical trials for Diamyd® are being conducted in several countries, including Sweden, the United States, and Spain. The trials are designed to evaluate the safety and efficacy of the vaccine in individuals with newly diagnosed Type 1 diabetes.

Other Projects[edit | edit source]

In addition to Diamyd®, the company is also involved in the development of other pharmaceutical treatments for diabetes and serious inflammatory diseases. These include Remygen®, a regenerative medicine project, and GABA, a project focused on the development of a drug for the treatment of inflammatory diseases.